Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer
Status:
Unknown status
Trial end date:
2021-01-02
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test to see if Gadoxetate Sodium is a useful
contrast agent for detecting prostate cancer during magnetic resonance imaging (MRI).
Gadoxetate Sodium is an FDA approved contrast agent that is currently used to detect liver
cancer. Gadoxetate Sodium shows promise in identifying more aggressive prostate cancers at
earlier stages. The study will also test to see if specific genes are expressed in the left
over tissue samples from previous prostate fusion biopsy. The investigators hypothesize that
Gadoxetate Sodium-enhanced MRI can differentiate aggressive prostate cancer and predict its
early recurrence.